Meningitis Treatment Guidelines

Introduction

• Bacterial meningitis is a serious infection that requires prompt treatment, with guidelines supported by the British Medical Journal, the Clinical Microbiology and Infection guidelines, the Infectious Diseases Society of America, and the American Academy of Neurology 1, 2, 3, 4

Empirical Antibiotic Regimens

• For patients over 50 years with suspected meningitis, the recommended empirical antibiotic regimen is ceftriaxone 2g IV every 12 hours (or cefotaxime 2g IV every 6 hours) PLUS ampicillin/amoxicillin 2g IV every 4 hours PLUS vancomycin 15-20mg/kg IV every 12 hours, as recommended by the Infectious Diseases Society of America 3
• Third-generation cephalosporins, such as ceftriaxone, provide excellent coverage against common meningeal pathogens, including pneumococci and meningococci, with good CSF penetration 3
• The American College of Physicians recommends an age-stratified empirical antibiotic regimen for bacterial meningitis, with adults 18-50 years receiving ceftriaxone plus vancomycin, while adults >50 years or immunocompromised patients should receive ceftriaxone plus vancomycin plus ampicillin/amoxicillin to cover Listeria 2
• Risk factors for Listeria include diabetes mellitus, immunosuppressive therapy, cancer, or other immunocompromising conditions 2
• First-line treatment for neonates is ampicillin plus cefotaxime, which should be initiated immediately upon clinical suspicion without waiting for diagnostic confirmation, as recommended by the Clinical Microbiology and Infection guidelines and supported by the Infectious Diseases Society of America and the American Academy of Neurology 2, 3, 4
• First-line therapy for children (1 month to 18 years) is ceftriaxone or cefotaxime plus vancomycin when pneumococcal meningitis cannot be ruled out, as recommended by the American Academy of Pediatrics and the Infectious Diseases Society of America 4, 2
• For adults (18-50 years) without risk factors for Listeria, the recommended regimen is Ceftriaxone 2g IV q12h or cefotaxime 2g IV q4-6h, with addition of vancomycin 15-20 mg/kg IV q8-12h in areas with high pneumococcal resistance, as recommended by the Infectious Diseases Society of America 2
• For adults >50 years or immunocompromised, the recommended regimen is Ceftriaxone or cefotaxime PLUS Vancomycin or rifampicin PLUS Amoxicillin/ampicillin 2g IV q4h (for Listeria coverage), with a high strength of evidence supporting this approach 2, 4

Special Considerations

• If the patient has traveled to a country with high rates of pneumococcal resistance within the last 6 months, vancomycin must be included in the regimen, according to the World Health Organization guidelines 3
• For patients with severe penicillin/cephalosporin allergy, chloramphenicol and co-trimoxazole can be used as alternative treatments, as suggested by the European Centre for Disease Prevention and Control 3
• Alternative therapy for neonates is ampicillin plus an aminoglycoside (gentamicin 2.5 mg/kg IV q12h for <1 week; q8h for 1-4 weeks), as recommended by the American Academy of Pediatrics 5
• Alternative therapy for children in areas with high pneumococcal resistance is to add rifampicin 10 mg/kg IV q12h (up to 600 mg/day), as recommended by the Infectious Diseases Society of America and the American Academy of Pediatrics 4, 2

Treatment Duration

• Initial empirical therapy should continue until culture results are available, and once the pathogen is identified, adjust therapy according to susceptibility patterns, with treatment durations ranging from 5-14 days, as recommended by the Infectious Diseases Society of America 3
• The standard duration of antimicrobial treatment is 10-14 days for most pathogens, but can be adjusted based on clinical response and identified pathogen, with specific durations recommended for pneumococcal meningitis (10-14 days), meningococcal meningitis (7 days), staphylococcal meningitis (at least 14 days), and culture-negative cases (at least 14 days), as recommended by the Clinical Microbiology and Infection guidelines 2
• The following table summarizes the treatment duration and adjustment recommendations:

Adjunctive Therapy

• Dexamethasone should be started with the first dose of antibiotics or up to 4 hours after, with a dose of 0.15 mg/kg IV q6h for 2-4 days in children, as recommended by the American Academy of Pediatrics, with a moderate strength of evidence supporting its use 4, 6
• Administer dexamethasone 10mg IV q6h for 4 days, starting before or with the first antibiotic dose, and consider stopping if the causative organism is neither H. influenzae nor S. pneumoniae, with a moderate strength of evidence supporting its use 2, 6

Management of Complications

• For signs of shock, the British Medical Journal recommends administering rapid infusion of intravenous fluids as isotonic crystalloid or colloid solution up to 60 ml/kg, given as three boluses of 20 ml/kg, with reassessment after each bolus 1
• In cases of fluid-resistant shock, the British Medical Journal suggests considering early ventilatory support after inotropes are started 1
• For refractory hypotension (inotrope-resistant shock), the British Medical Journal recommends intravenous vasopressin and steroid dose titration as appropriate rescue strategies 1
• Close neurological monitoring with frequent assessments is crucial for managing meningitis with unilateral edema, with consideration of neurosurgical consultation if significant mass effect is present, and maintaining head elevation at 30 degrees and avoiding hypotonic fluids that may worsen cerebral edema are also important considerations, as recommended by the Clinical Microbiology and Infection guidelines 2

Public Health Considerations

• The British Medical Journal recommends liaising with the local public health department for appropriate public health actions 1
• The British Medical Journal suggests offering prophylaxis to close contacts who had prolonged contact in a household setting with a child with meningococcal disease during the seven days before onset of illness 1

Outpatient Therapy

• Outpatient therapy can be considered for patients who are clinically stable after initial inpatient treatment, with a moderate strength of evidence supporting this approach, as recommended by the Infectious Diseases Society of America 3